Executive SummaryNDA for the treatment of endometriosis is expected to be filed by the end of the company's current fiscal year (July 31), Syntex Chairman Albert Bowers told analysts in New York Jan. 18. Bowers also noted that the company has four NDAs pending at the agency, including Cardene, Ticlid, Gardrin and Toradol. The injectable pain killer Toradol (ketorolac) has been given a 1-B rating by the agency, Bowers said.
You may also be interested in...
As part of its response to the coronavirus outbreak, Medicines for Europe has set out a series of policy recommendations that it says could help to mitigate the risks of COVID-19.
The coronavirus COVID-19 outbreak poses a “limited immediate risk” to European production and supplies of off-patent drugs, according to industry association Medicines for Europe. However, if the situation continues for an extended period an “important impact” cannot be ruled out.
ABHI director of value and access Luella Trickett talks about the importance of real-world evidence in product development and value-based procurement in secondary care in the UK.